Ingevity CorporationNGVTNYSE
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank38
3Y CAGR-58.7%
5Y CAGR-40.8%
Studio
Year-over-Year Change

Year-over-year research & development expense growth

3Y CAGR
-58.7%/yr
vs +15.4%/yr prior
5Y CAGR
-40.8%/yr
Recent deceleration
Acceleration
-74.1pp
Decelerating
Percentile
P38
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
20251.07%
2024-11.64%
20234.95%
202215.21%
202116.37%
202014.72%
2019-8.37%
20188.59%
2017160.53%
201610.14%